CYCC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYCC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cyclacel Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-6.23. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-27.08.
Cyclacel Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2023 was $-6.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-27.08.
Cyclacel Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-5.86. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -26.65.
During the past 3 years, the average EPS without NRI Growth Rate was 20.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Cyclacel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 55.50% per year. The lowest was -67.50% per year. And the median was 27.20% per year.
The historical data trend for Cyclacel Pharmaceuticals's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | -147.60 | -51.30 | -31.35 | -28.70 | -26.75 |
Cyclacel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EPS (Basic) | Get a 7-Day Free Trial | -9.00 | -7.05 | -6.60 | -7.20 | -6.23 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Cyclacel Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
Basic EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-22.555 | - | 0.201) | / | 0.851 | |
= | -26.74 |
Cyclacel Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2023 is calculated as
Basic EPS (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-5.271 | - | 0.05) | / | 0.888 | |
= | -5.99 |
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals (NAS:CYCC) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Spiro Rombotis | director, officer: President & C.E.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Paul Mcbarron | director, officer: E.V.P., Finance & C.O.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Kenneth M. Ferguson | director | 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121 |
Sam L Barker | director | 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Karin L Walker | director | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Mark Kirschbaum | officer: Chief Medical Officer | 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Eastern Capital Ltd | 10 percent owner | 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kevin C Tang | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Partners Lp | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Management Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Portfolio Services Ltd. | 10 percent owner | 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kenneth Bryan Dart | 10 percent owner | P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206 |
Lloyd Sems | director | C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-30-2023
By Value_Insider Value_Insider • 10-24-2022
By sperokesalga sperokesalga • 05-04-2023
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By PurpleRose PurpleRose • 08-10-2022
By Marketwired • 08-09-2023
By GuruFocusNews GuruFocusNews • 05-21-2022
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 08-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.